Navigating a storm that threatens American biotechnology
Over the past four decades, David Beier has observed and participated in the evolution of the US biotechnology industry for several key vantage points. The industry’s success and freedom to innovate, he says, has been underpinned by – and helped create – a marketplace that was open enough to fully reward risk-taking investors devoting capital to cutting edge science. Today, that success faces new threats.
What happens if President Biden’s drug pricing plan passes?
If the Biden drug plan passes, the United States will be consciously volunteering to put less capital to work in a large industry where we lead the world. No real argument can stand against the fact that less capital means fewer new products for patients.